MedCrypt Inc., the main supplier of proactive security answers for the medical care space, today declared Accuray has picked MedCrypt's Software Bill of Materials (SBOM) and Vulnerability Tracking Software, Heimdall, to help upgrade observing the advanced security stance of the organization's arrangement of radiation therapy conveyance, arranging, and information the executives arrangements. Accuray innovations empower clinical consideration groups to convey progressed malignancy therapies to patients, limiting the measure of sound tissue encompassing tumors that is presented to superfluous high-portion radiation.
"The work being done to treat cancer is some of the most important work in the healthcare industry and we are proud to partner with Accuray to help enhance the security posture of its life-saving technologies," said Mike Kijewski, CEO of MedCrypt. "Our solution gathers critical vulnerability data from the National Vulnerability Database, giving us an accurate rundown of potential exposures, so we can respond quickly if a problem is found. With MedCrypt focused on the security aspect, Accuray can focus on their clinical expertise."
Accuray advancements in radiotherapy incorporate two of the most exact and exact radiation therapy conveyance frameworks in the business — the CyberKnife® and the TomoTherapy® stages, including the cutting edge Radixact® System — empowering clinicians to convey more customized and more viable therapies. MedCrypt's Heimdall programming will contrast these frameworks' SBOM with the National Vulnerability Database from the National Institute of Standards and Technology to recognize known programming weaknesses. In the event that a realized weakness is distinguished in the SBOM, MedCrypt will inform Accuray with alarms, and the on-going assistance will consistently screen for weaknesses in any SBOM transferred into the framework.
"Patients treated with the Accuray systems are our number one priority and augmenting the security of our technologies against potential vulnerabilities is increasingly important," said Frank Valentino, vice president, research & development at Accuray. "We are very pleased to be working with MedCrypt. With their software, we can easily monitor our SBOMs and take immediate action if a vulnerability is identified. We can focus on creating innovative solutions for patient treatments, knowing our technologies are being monitored and protected."
MedCrypt offers proactive cybersecurity solutions for medical device manufacturers to build safe and secure medical devices by design. The company recently launched its API verification tool to help secure Liberate's VentFree™ Respiratory Muscle Stimulator, a device intended to be used to treat COVID-19 patients. MedCrypt also welcomed Michael McNeil to its board of directors, reaffirming its commitment to proactive cybersecurity and the promise that clinical functionality, patient safety, and care delivery are always the highest priority.
About MedCrypt, Inc.
MedCrypt is a San Diego-based company that provides proactive security for healthcare technology. MedCrypt's platform brings core cybersecurity features to medical devices with just a few lines of code, ensuring devices are secure by design. MedCrypt announced a $5.3 million Series A funding round in May of 2019, bringing the total funds raised to $9.4 million with participation from Eniac Ventures, Section 32, Y Combinator, and more. The company is based in San Diego, California.